Banka Bio FY26: EBITDA Recovery Is Visible, FY27 Must Prove Cash Conversion

Banka Bio walked into its FY 2025-26 AGM with a simple message: earnings have recovered, but FY27 needs to turn contracted work into collected cash. The company ended FY26 with total income of ₹58.39 crore, up 7.1 percent year on year, while EBITDA swung to ₹6.49 crore from a negative ₹2.55 crore in FY25. Group PAT moved into the black at ₹0.39 crore versus a loss of ₹8.91 crore in the prior year.

Those numbers mark a clear inflection. But the presentation is equally candid about what remains unresolved. Profit before tax was still slightly negative at minus ₹0.26 crore, improved from minus ₹9.12 crore. Net operating cash flow was only ₹1.05 crore, and the company disclosed that ₹6.10 crore was absorbed by working capital. In other words, the income statement is healing faster than the cash flow statement.

The company’s narrative ties the recovery to execution discipline and procurement, with selective growth. And it frames FY27 as a proof year where the operating platform, including Megaliter, has to demonstrate the full cycle: commission assets, bill customers, and collect cash reliably enough to deliver sustainable profit before tax.

The platform: Banka Bio executes, Megaliter funds and contracts

A key element of the AGM story is the integrated model built with Megaliter Varunaa. Banka Bio positions itself as the operating arm, the entity that builds, operates, and maintains water and sanitation assets. Megaliter is described as the holding and contracting arm, responsible for funding assets, owning them, contracting with customers, and managing collections.

This split is meant to create a recurring-services business rather than a one-time project execution profile. Banka Bio highlights engineering and commissioning capability and long-term service delivery as its operational strengths. Megaliter is presented as the asset and contract platform that can support long-tenure service contracts, with a focus on customer contracts and collections.

The presentation uses a representative project example to show the standard operating model. In that example, a premium residential project was commissioned in February 2025, structured with a 120-month contract tenure, and disclosed an LTV contract income of ₹14.1 crores. The customer signs a long-term service contract and pays a recurring subscription. Megaliter funds and owns the treatment asset, manages the contract, and collects fees. Banka Bio executes the build and commissioning and then provides operations and maintenance.

This matters for investors because it explains why a large contracted portfolio does not automatically translate into near-term profits or cash. The model is long-duration, and value is realised through commissioning performance, service uptime, billing acceptance, and collections discipline.

Megaliter: large contracted LTV, but conversion is the real job

Megaliter is described as having 16 contracted projects and a portfolio lifetime value of ₹122 crore. Of these, 14 projects were operating and 2 were work in progress. The company also noted that roughly 80 percent of revenue remained to be recognised across this portfolio, underscoring the multi-year nature of the contracted stream.

Management emphasised that contracted activity is only an opportunity. Delivery, economics, and collections determine the outcome. This is consistent with the company’s focus on the conversion chain: signed to funded to commissioned to operating to billed to collected.

The presentation also acknowledges that project-level EBITDA, company-level PAT, and cash available to investors are different measures. A project might show strong EBITDA margins, but depreciation, financing costs, taxes, capex timing, and collection delays can materially change what appears at the consolidated profit line and in operating cash flow.

Megaliter disclosed FY26 turnover of ₹5.86 crore and PAT of ₹14.80 lakh. That suggests the platform is still in an early stage of scaling, where the contracted base is meaningful, but the annual revenue recognition is not yet reflective of the full LTV potential.

The company disclosed an estimated project-level post-tax IRR of 20 percent plus, based on current project assumptions and subject to operating performance, collections, capex, and financing. This is an investor-oriented disclosure because it signals that the model is being evaluated as an annuity-like investment portfolio. But it also highlights the sensitivity of returns to execution and collections.

FY26 performance: income growth and an EBITDA swing, but pre-tax profit still pending

Banka Bio’s FY26 results show a classic recovery pattern. Total income rose to ₹58.39 crore from ₹54.50 crore. Net operating revenue increased from ₹54.17 crore to ₹57.09 crore, up 5.4 percent. EBITDA improved sharply to ₹6.49 crore from a loss of ₹2.55 crore.

However, the company is careful in how it describes this improvement. FY26 EBITDA excluding other income was ₹5.20 crore. Other income in FY26 included ₹0.84 crore of award income, which management explicitly notes is not customer subscription revenue. This distinction is important because it separates structural operating improvement from one-off or non-core inflows.

At the bottom line, group PAT was ₹0.39 crore, and earnings per share improved from minus ₹8.21 to ₹0.32. But profit before tax remained slightly negative at minus ₹0.26 crore. For FY27, the company identifies pre-tax profitability as the next milestone.

A disclosed EBITDA bridge shows what drove the year-on-year shift of ₹9.04 crore in EBITDA. The key components included the absence of FY25 bad-debt expense, higher other income, and other operating movements net. The way this bridge is presented points to a central question for FY27: how much of the improvement is repeatable, and how much depends on the prior-year comparison base.

Financial summary

Cash conversion: the constraint is working capital and collections

If the FY26 message is about earnings recovery, the FY27 message is about converting that recovery into cash. The presentation lays out the mechanics clearly.

Operating profit before working-capital changes was ₹6.25 crore. But working capital absorbed ₹6.10 crore, leaving net operating cash flow at ₹1.05 crore. The company also noted ₹0.90 crore of net income-tax refunds and ₹0.15 crore before tax movements.

The working capital detail provides additional context. Trade receivables stood at ₹29.15 crore and contract assets at ₹9.42 crore as of 31 March 2026. These balances matter because they indicate where profits and project progress are sitting on the balance sheet rather than in cash. Contract assets often reflect revenue recognised or work completed that has not yet been billed or accepted. Receivables indicate billing has happened, but cash collection is pending.

The company explicitly frames billing, collections, and working-capital discipline as key execution priorities. This is consistent with the broader conversion framework it presented for Megaliter, where value is realised only after bills are accepted and cash is collected.

The cash profile also shows investment requirements. Purchases of property, plant and equipment were ₹6.00 crore in FY26. For a business combining build, own, and operate elements, capex and replacement capex timing can create a persistent gap between accounting profit and free cash flow. Management’s emphasis on funding discipline suggests it wants to avoid stretching the balance sheet ahead of collections.

Balance sheet: liquidity improved, leverage still needs discipline

Banka Bio disclosed that funding strengthened liquidity in FY26. Consolidated gross borrowings increased to ₹39.35 crore from ₹34.25 crore in FY25. But cash and cash equivalents rose sharply to ₹10.21 crore from ₹0.25 crore. This shift helped adjusted net debt decline to ₹28.88 crore from ₹30.18 crore, and adjusted net debt to equity improved to 0.73x from 0.96x.

The company also disclosed ₹10 crore of FY26 Megaliter Varunaa equity proceeds from outside shareholders. That data point supports the idea that Megaliter is being built as a funded platform, not just an internal project unit. But it also reinforces why investor attention should focus on project economics and cash conversion: external equity can support the buildout, but long-term value creation depends on the recurring cash yield of the contracted portfolio.

Management said it will continue to match Megaliter investment and debt to project economics. In practice, that signals a desire to align capex and funding with contract visibility and collection performance, rather than growing the portfolio faster than the cash cycle can sustain.

Order book: near-term execution pipeline, distinct from LTV

Alongside long-duration LTV, Banka Bio disclosed an unexecuted order book of ₹107 crore across Banka RAIL and Banka WaSH, with ₹70 crore identified for the next 12 months and a Banka WaSH order book of ₹56 crore as of 31 March 2026.

The company is explicit that order book and LTV are distinct and should not be added together. That statement is useful because it reduces the risk of double counting. Order book represents unexecuted project work, while LTV represents contracted long-tenure service revenues, often spanning years. Both are conversion opportunities, but they convert through different processes and timeframes.

The presentation lists current work in progress items in the company project schedule, including a commercial asset in Hyderabad under execution, commercial assets in Mumbai and Bengaluru under commissioning, and QWS Kerala in commissioning. It also outlines the execution ladder that investors should watch: complete, commission, start service, bill, collect.

This ladder ties the entire AGM thesis together. The company is not only talking about growth, it is talking about turning project milestones into billing events and then into cash, and doing so consistently.

FY27 scorecard: commission, collect, and deliver sustainable PBT

For FY27, the company’s priorities are framed as a scorecard with execution focus and progress indicators.

Commissioning the portfolio is the first step, because work-in-progress projects must move into service before recurring revenue can scale. The company links this to indicators like commissioning progress, projects billing, and recurring revenue.

Improving collections is the second step. Management points to contract assets, receivable ageing, and operating cash as the indicators that will show whether the business is converting work into cash.

Strengthening profitability is the third step, with a focus on PBT, EBITDA excluding other income, and attributable PAT. The choice of these metrics suggests management wants investors to judge FY27 on core profitability, not on non-operating income.

Maintaining funding discipline and digitising operations round out the priorities. Funding discipline will be visible through capex, commitments, debt, and guarantees. Digitisation is framed through performance monitoring across assets, including assets monitored, uptime, and service performance.

The company also referenced a 2030 vision of 15 plus billion litres annual water recycling as an operating ambition. While FY27 guidance is not quantified in the presentation, the ambition provides a long-range context for why recurring service contracts and asset monitoring matter.

Investor takeaways: what to watch after the recovery

Banka Bio’s FY26 results show an operational recovery, but the investment case is now moving into a more demanding phase. The company has built an integrated platform, but it needs to show that contracted LTV can become stable cash generation.

Three practical investor takeaways follow from the presentation.

First, the income statement recovery is real, but the quality of earnings needs monitoring. EBITDA improved materially, yet FY26 included other income, and PBT is still slightly negative. FY27 needs to demonstrate sustainable pre-tax profitability.

Second, collections and working capital are the key swing factors. With ₹29.15 crore of receivables and ₹9.42 crore of contract assets at year end, the difference between reported earnings and free cash flow will depend on billing acceptance, receivable ageing, and actual collection cycles.

Third, the portfolio story is credible only if execution milestones keep moving. Megaliter’s ₹122 crore LTV and 16 contracted projects show long-tenure demand, while the ₹107 crore order book shows near-term work. But both require commissioning, service delivery, and disciplined funding to become durable returns.

The company’s closing theme, consistency that compounds, is ultimately a cash flow statement theme. The platform is built. FY27 is where the model has to show repeatability: commission projects, operate plants, collect cash, and deliver sustainable PBT.